Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds’ drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Company profile
Ticker
DRUG
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
D
$54.16 k in equity / options / securities to be acquired, 2 investors
2 May 24
6-K
Condensed Interim Consolidated Financial Statements
12 Feb 24
20-F
2023 FY
Annual report (foreign)
29 Dec 23
6-K
Bright Minds Announces Closing of Non-Brokered Private Placement Fully Subscribed by Management
22 Dec 23
6-K
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management
8 Dec 23
6-K
Condensed Interim Consolidated Financial Statements
14 Aug 23
6-K
Current report (foreign)
8 Aug 23
6-K
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
20 Jul 23
6-K
Bright Minds Announces Effective Date of Share Consolidation
12 Jul 23
6-K
Bright Minds Announces Proposed Share Consolidation
22 Jun 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Sep 22 | Sep 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
News
"FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month" - Marijuana Moment
7 May 24
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
17 Apr 24
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
29 Mar 24
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
20 Mar 24
Reported Earlier, 'Indiana Lawmakers Send Psilocybin Research Funding Bill To Governor' - Marijuana Moment
14 Mar 24